Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model

Bone Marrow Transplantation

Volumn 32, Issue 1, 2003, Pages 49-56

  Hartung, G ^a   Zeis, M ^b   Glass, B ^c   Dreger, P ^b   Steinmann, J ^d   Schmitz, N ^b   Uharek, L ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b ST GEORGE HOSPITAL   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

Cellular composition; G CSF; GvHD; GvL; PBPCT; SCF

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG UTILIZATION; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; T LYMPHOCYTE;

ANIMALS; CELL COUNT; DRUG THERAPY, COMBINATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; IMMUNE SYSTEM; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL FACTOR; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 0038493791     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704072     Document Type: Review

References (46)

1. Schmitz N, Dreger P, Suttorp, M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
2. Dreger P, Glass B, Uharek L et al. Allogenic transplantation of mobilized peripheral blood progenitor cells: towards tailored cell therapy. Int J Hematol 1997; 66: 1-11.
3. Glass B, Uharek L, Zeis M et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. Blood 1997; 90: 1694-1700.
4. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
5. Fischmeister G, Gadner H. Granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor for collection of peripheral blood progenitor cells from healthy donors. Cur Opin Hematol 2000; 7: 150-155.
6. Geissler K, Peschel C, Niederwieser D et al. Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 1996; 87: 2732-2739.
7. Bodine DM, Seidel NE, Zsebo KM, Orlic D. In vivo administration of stem cell factor to mice increases the absolute number of pluripotent hematopoietic stem cells. Blood 1993; 82: 445-455.
8. Molineux G, McCrea C, Yan XQ et al. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 1997; 89: 3998-4004.
9. Mauch P, Lamont C, Neben TY et al. Hematopoietic stem cells in the blood after stem cell factor and interleukin-11 administration: evidence for different mechanisms of mobilization. Blood 1995; 86: 4674-4680.
10. Suzuki H, Ikebuchi K, Wada Y et al. An increase in peripheral blood progenitor cells in primates by coadministration of recombinant human interleukin 6 and recombinant human granulocyte colony-stimulating factor. Transplantation 1997; 64: 1468-1473.
11. Grzegorzewski KJ, Komschlies KL, Franco JL et al. Quantitative and cell-cycle differences in progenitor cells mobilized by recombinant human interleukin-7 and recombinant human granulocyte colony-stimulating factor. Blood 1996; 88: 4139-4148.
12. Jackson JD, Yan Y, Brunda MJ et al. Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood 1995; 85: 2371-2376.
13. Funakoshi S, Taub DD, Anver MR et al. Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. J Clin Invest 1997; 99: 484-491.
14. Champlin R, Giralt S, Gajewski J. T cells, graft-versus-host disease and graft-versus-leukemia: innovative approaches for blood and marrow transplantation. Acta Haematol 1996; 95: 157-163.
15. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
16. Rondelli D, Raspadori D, Anasetti C et al. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 1998; 22: 631-637.
17. Sloand EM, Kim S, Maciejewski JP et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269-2274.
18. Pulendran B, Banchereau J, Burkeholder S et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000; 165: 566-572.
19. Arpinati M, Green CL, Heimfeld S et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490.
20. Mielcarek M, Martin PJ, Torok-Storb B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997; 89: 1629-1634.
21. Uharek L, Glass B, Zeis M et al. Abrogation of graft-vs-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT). Exp Hematol 1998; 26: 93-99.
22. Kim KJ, Kannellopoulus-Langevin C, Mervin RM et al. Establishment and characterization of Balb/c lymphoma lines with B cell properties. J Immunol 1979; 122: 549-554.
23. Molineux G, Pojda Z, Hampson In et al. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 1990; 76: 2153-2158.
24. Bodine DM, Seidel NE, Orlic D. Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow. Blood 1996; 88: 89-97.
25. Leary AG, Zeng HQ, Clark SC, Ogawa M. Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors. Proc Natl Acad Sci U S A 1992; 89: 4013-4017.
26. deRevel T, Appelbaum FR, Storb R et al. Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 1994; 83: 3795-3799.
27. Yan XQ, Hartley C, McElroy P et al. Peripheral blood progenitor cells mobilized by recombinant human granulocyte colony-stimulating factor plus recombinant rat stem cell factor contain long-term engrafting cells capable of cellular proliferation for more than two years as shown by serial transplantation in mice. Blood 1995; 85: 2303-2307.
28. Uharek L, Gassmann W, Glass B et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 1992; 79: 1612-1621.
29. Begley CG, Basser R, Mansfield R et al. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans. Blood 1997; 90: 3378-3389.
30. Stiff P, Gingrich R, Luger S et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 26: 471-481.
31. Briddell RA, Hartley CA, Smith KA, McNiece IK. Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. Blood 1993; 82: 1720-1723.
32. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
33. Körbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation: Peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
34. Pan L, Delmonte Jr J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.
35. Zeng D, Dejbakhsh JS, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transplantation. Blood 1997; 90: 453-463.
36. Uharek L, Zeis M, Hartung G et al. Induction of a T helper 2 (Th2) response in CD4+ donor cells leads to enhanced graft-versus-leukemia (GvL) activity and inhibits graft-versus-host disease (GvHD) after allogeneic stem cell transplantation. Blood 1997; 90(Suppl. 1): 204 (abstr).
37. Bluman EM, Schnier GS, Avalos BR et al. The c-kit ligand potentiates the allogeneic mixed lymphocyte reaction. Blood 1996; 88: 3887-3893.
38. Rodewald HR, Kretzschmar K, Swat W, Takeda S. Intra-thymically expressed c-kit ligand (stem cell factor) is a major factor driving expansion of very immature thymocytes in vivo. Immunity 1995; 3: 313-319.
39. Zeis M, Uharek L, Glass B et al. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukemia effect in mice. Br J Haematol 1997; 96: 757-761.
40. Matos ME, Schnier GS, Beecher MS et al. Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 1993; 178: 1079-1084.
41. Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H. Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1995; 85: 3538-3546.
42. Miller JS, Prosper F, McCullar V. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood 1997; 90: 3098-3105.
43. Tsai M, Shih LS, Newlands GF et al. The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. J Exp Med 1991; 174: 125-131.
44. Shelburne CP, Ryan JJ. The role of Th2 cytokines in mast cell homeostasis. Immunol Rev 2001; 179: 82-93.
45. Gagari E, Tsai M, Lantz CS et al. Differential release of mast cell interleukin-6 via c-kit. Blood 1997; 89: 2654-2663.
46. Volpi I, Perruccio K, Tosti A et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001; 97: 2514-2521.